Evaluation of endoscopic reintervention for self-expandable metallic stent obstruction after stent-in-stent placement for malignant hilar biliary obstruction.


Journal

Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 6 4 2019
medline: 20 12 2019
entrez: 6 4 2019
Statut: ppublish

Résumé

Bilateral self-expandable metallic stent (SEMS) placement is effective for long-term management of unresectable malignant hilar biliary obstruction (UMHBO). However, endoscopic reintervention (ERI) for bilateral SEMSs is not well-studied. This study aimed to evaluate ERI efficacy after stent-in-stent placement. Data of 31 patients who underwent ERI from May 2000 to July 2018 were analyzed. The technical success rate was 80.7% (25/31) and no adverse events occurred. The functional success rate was 100% (25/25). In a multivariate logistic regression analysis, the angle between the bilateral SEMSs (ABBS) >104° (odds ratio 50.49, 95% CI 3.370-2131, P = 0.0039) and overgrowth (odds ratio 25.70, 95% CI 1.121-1234, P = 0.0423) were risk factors for ERI failure. Multiple liver metastases, which sometimes cause overgrowth, were also risk factors. After ERI, some patients underwent additional SEMS (n = 4), plastic stent (n = 14) placement, or internal cleaning of the initial SEMS alone (n = 7). There were no significant intergroup differences in the 50% time to recurrent biliary obstruction. ABBS >104° and overgrowth were risk factors for ERI failure after stent-in-stent placement. In the decision-making process for initial SEMS placement for UMHBO, patient condition should be considered, including the angle between bilateral bile ducts and multiple liver metastases.

Sections du résumé

BACKGROUND BACKGROUND
Bilateral self-expandable metallic stent (SEMS) placement is effective for long-term management of unresectable malignant hilar biliary obstruction (UMHBO). However, endoscopic reintervention (ERI) for bilateral SEMSs is not well-studied. This study aimed to evaluate ERI efficacy after stent-in-stent placement.
METHODS METHODS
Data of 31 patients who underwent ERI from May 2000 to July 2018 were analyzed.
RESULTS RESULTS
The technical success rate was 80.7% (25/31) and no adverse events occurred. The functional success rate was 100% (25/25). In a multivariate logistic regression analysis, the angle between the bilateral SEMSs (ABBS) >104° (odds ratio 50.49, 95% CI 3.370-2131, P = 0.0039) and overgrowth (odds ratio 25.70, 95% CI 1.121-1234, P = 0.0423) were risk factors for ERI failure. Multiple liver metastases, which sometimes cause overgrowth, were also risk factors. After ERI, some patients underwent additional SEMS (n = 4), plastic stent (n = 14) placement, or internal cleaning of the initial SEMS alone (n = 7). There were no significant intergroup differences in the 50% time to recurrent biliary obstruction.
CONCLUSIONS CONCLUSIONS
ABBS >104° and overgrowth were risk factors for ERI failure after stent-in-stent placement. In the decision-making process for initial SEMS placement for UMHBO, patient condition should be considered, including the angle between bilateral bile ducts and multiple liver metastases.

Identifiants

pubmed: 30950234
doi: 10.1002/jhbp.626
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

211-218

Informations de copyright

© 2019 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Auteurs

Mitsuru Okuno (M)

Department of Gastroenterology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu City, Gifu 500-8513, Japan.

Tsuyoshi Mukai (T)

Department of Gastroenterology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu City, Gifu 500-8513, Japan.

Takuji Iwashita (T)

First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.

Hironao Ichikawa (H)

Department of Gastroenterology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu City, Gifu 500-8513, Japan.

Yuhei Iwasa (Y)

Department of Gastroenterology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu City, Gifu 500-8513, Japan.

Naoki Mita (N)

First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.

Kensaku Yoshida (K)

First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.

Keisuke Iwata (K)

Department of Gastroenterology, Gifu Prefecture General Medical Center, Gifu, Japan.

Eiichi Tomita (E)

Department of Gastroenterology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu City, Gifu 500-8513, Japan.

Masahito Shimizu (M)

First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH